Weight Loss — Symptom Overview

Table of Contents

  1. Definitions and Red Flags
  2. Malignancy as a Cause
  3. Psychiatric and Psychological Causes
  4. Endocrine and Metabolic Causes
  5. Gastrointestinal and Malabsorption Causes
  6. Chronic Disease and Medications
  7. Diagnostic Workup
  8. Management and Nutritional Support
  9. Connections
  10. Key Research Papers
  11. Featured Videos

Definitions and Red Flags

Clinically significant unintentional weight loss is defined as loss of 5% or more of body weight within 6–12 months, or more than 10 pounds unintentionally. This threshold always warrants medical evaluation — no benign cause for significant involuntary weight loss should be assumed without a thorough workup.

Red flags suggesting malignancy include older age, male sex, smoking history, night sweats, lymphadenopathy, palpable mass, hemoptysis, melena, dysphagia, and constitutional B symptoms (fever, drenching night sweats, weight loss). When any of these accompany weight loss, expedited cancer screening is indicated.

A useful clinical mnemonic for the causes of weight loss — especially in elderly patients — is MEALS ON WHEELS:

Epidemiologically, the causes of significant unintentional weight loss divide into four roughly equal categories: malignancy (~25%), psychiatric and social causes (~25%), organic non-cancer conditions (~25%), and unexplained (~25%). Importantly, the unexplained category often follows a benign course with conservative follow-up when initial screening is negative.

Back to Table of Contents

Malignancy as a Cause

Cancer cachexia is a cytokine-mediated wasting syndrome distinct from simple starvation. Pro-inflammatory cytokines — particularly IL-6, TNF-α, IL-1, and IFN-γ — drive simultaneous loss of skeletal muscle and adipose tissue alongside profound anorexia. Unlike simple starvation, cancer cachexia is characterized by protein catabolism that predominates over fat loss, and it cannot be reversed by nutritional support alone because the underlying inflammatory drive persists.

Cancers most strongly associated with cachexia include pancreatic (up to 90% of patients), gastric, small cell lung, and esophageal. Specific cancer presentations to recognize:

Cancer screening workup in the setting of unexplained weight loss includes: CBC with differential (anemia of chronic disease, unexplained leukocytosis or thrombocytosis), comprehensive metabolic panel, LDH (elevated in lymphoma and tumor lysis), PSA in men over 45, CEA and CA19-9 for gastrointestinal malignancy, CT chest-abdomen-pelvis with contrast as a comprehensive first screen for occult malignancy, endoscopy (upper and/or lower) when GI symptoms are present, and PET-CT in diagnostically challenging cases where initial imaging is negative but suspicion remains high.

Back to Table of Contents

Psychiatric and Psychological Causes

Depression is the most common psychiatric cause of unintentional weight loss. Neurovegetative symptoms of depression — decreased appetite, psychomotor retardation, anhedonia, disrupted sleep — converge to reduce caloric intake. PHQ-9 screening is the standard tool; a score of 10 or above warrants further assessment. Successful antidepressant treatment typically restores appetite and weight.

Anorexia Nervosa is a potentially life-threatening eating disorder defined by restriction of caloric intake, body image disturbance, and intense fear of weight gain. DSM-5 distinguishes two subtypes: restrictive type (dietary restriction and excessive exercise) and binge-purge type. Female predominance is approximately 10:1, with onset typically in adolescence or young adulthood. Medical complications are extensive:

Additional psychiatric and cognitive causes include anxiety disorders (with somatic preoccupation), somatization, and dementia — patients with cognitive decline may forget to eat, develop aversions or swallowing difficulties, or lose the capacity to prepare food independently.

Back to Table of Contents

Endocrine and Metabolic Causes

Hyperthyroidism produces hypermetabolism and increased sympathomimetic activity, resulting in weight loss despite a paradoxically increased appetite — a critical diagnostic clue. Accompanying features include tachycardia, fine tremor, heat intolerance, diarrhea, and anxiety. Laboratory findings: suppressed TSH with elevated free T4 (and often elevated free T3). Graves disease is the most common cause in younger women; toxic multinodular goiter is more common in older patients.

Diabetes mellitus can present with significant weight loss when uncontrolled. In type 1 diabetes, glycosuria causes osmotic diuresis and loss of caloric substrate; combined with protein catabolism and fat breakdown, patients can lose substantial weight rapidly — sometimes presenting in diabetic ketoacidosis. Type 2 diabetes presenting with ketosis-prone disease (particularly in African American and Hispanic patients) can mimic type 1 in its weight loss presentation.

Adrenal insufficiency (Addison's disease) produces cortisol deficiency leading to anorexia, weight loss, profound fatigue, hyperpigmentation (primary adrenal failure), and orthostatic hypotension. Diagnosis: morning serum cortisol; confirmatory ACTH stimulation test (a cortisol rise of <9 μg/dL from a synthetic ACTH challenge indicates insufficiency).

Pheochromocytoma is a rare catecholamine-secreting adrenal tumor that drives hypermetabolism, causing weight loss alongside episodic or sustained hypertension, diaphoresis, and severe headache. Diagnosis: 24-hour urine metanephrines or plasma free metanephrines (more sensitive). Imaging with CT or MRI confirms the adrenal mass; MIBG scan detects extra-adrenal tumors.

Back to Table of Contents

Gastrointestinal and Malabsorption Causes

The key clue to malabsorption is weight loss despite adequate or even increased oral intake. The hallmark symptom is steatorrhea: pale, oily, foul-smelling, bulky stools that float — reflecting fat malabsorption. Patients may report frequent loose stools, bloating, and flatulence.

Celiac disease (gluten-sensitive enteropathy) causes T-cell-mediated destruction of small intestinal villi in response to dietary gluten. Initial screening: anti-tissue transglutaminase IgA antibody (anti-tTG IgA) plus total IgA level (to rule out IgA deficiency, which causes false-negative tTG). Confirmatory diagnosis requires duodenal biopsy showing villous atrophy and crypt hyperplasia. Presentation is heterogeneous — many patients have extraintestinal manifestations (iron deficiency anemia, osteoporosis, peripheral neuropathy, dermatitis herpetiformis) rather than classical diarrhea.

Inflammatory bowel disease, particularly Crohn's disease, produces weight loss through a combination of reduced intake (pain with eating), malabsorption (inflamed mucosa), and systemic inflammation. Crohn's is characterized by transmural inflammation that can affect any segment from mouth to anus, perianal disease, and skip lesions.

Exocrine pancreatic insufficiency (EPI) results from chronic pancreatitis, cystic fibrosis, or pancreatic resection — insufficient digestive enzymes lead to fat and protein malabsorption. Fecal elastase below 200 μg/g stool confirms EPI; treatment is pancreatic enzyme replacement therapy with meals.

Small intestinal bacterial overgrowth (SIBO) causes malabsorption through bacterial competition for nutrients and mucosal injury. Diagnosis by hydrogen/methane breath testing; standard treatment is rifaximin (a non-absorbable antibiotic).

Dysphagia from esophageal pathology — cancer, achalasia, peptic stricture, eosinophilic esophagitis — causes weight loss through mechanical restriction of oral intake rather than true malabsorption.

Back to Table of Contents

Chronic Disease and Medications

Chronic infections represent an underappreciated cause of weight loss:

Organ failure and chronic disease cachexia:

Medications that commonly cause anorexia or nausea leading to weight loss include: metformin (GI intolerance), SSRIs/SNRIs (transient early weight loss), stimulants (amphetamines, methylphenidate), digoxin (nausea, anorexia), antibiotics (dysgeusia, nausea), opioids (nausea, constipation-driven anorexia), chemotherapy, topiramate and zonisamide (used therapeutically for weight loss in epilepsy), and GLP-1 receptor agonists (semaglutide, liraglutide — intentional weight loss in metabolic disease, but weight loss may be undesired in frail elderly patients).

Back to Table of Contents

Diagnostic Workup

A structured approach minimizes missed diagnoses while avoiding unnecessary testing.

History (high yield): Timeline and pace of weight loss; intentional versus involuntary; dietary habits and recent changes; depression and anxiety screening (PHQ-9, GAD-7); alcohol and substance use; complete medication review including OTC and supplements; occupational and social history (food insecurity, isolation, bereavement); review of systems covering every organ system.

Physical examination: Lymphadenopathy (malignancy, infection); thyroid enlargement or nodule; abdominal mass or organomegaly; rectal examination (colorectal cancer); skin (jaundice suggesting hepatic/pancreatic disease; hyperpigmentation in Addison's; rashes in IBD or connective tissue disease); oral cavity (poor dentition, thrush, mucositis); temporal wasting and muscle bulk.

First-line laboratory evaluation:

Expanded workup when initial evaluation is unrevealing: CT chest-abdomen-pelvis with intravenous contrast (comprehensive screening for occult malignancy and adenopathy); age-appropriate cancer screening (colonoscopy, mammogram, Pap smear, PSA); upper endoscopy if dysphagia or upper GI symptoms are present; anti-tTG IgA for celiac disease; fecal elastase for EPI; HIV quantitative viral load if positive serology; morning cortisol and ACTH stimulation test if adrenal insufficiency is suspected; plasma free metanephrines if pheochromocytoma is considered; bone marrow biopsy if unexplained hematological abnormalities persist; PET-CT in cases where CT is negative but malignancy suspicion remains high.

Probability by age: In patients under 50, psychiatric causes (depression, eating disorders), hyperthyroidism, IBD, and malabsorption syndromes are disproportionately common. In patients over 65, malignancy, depression, cardiac and pulmonary disease, and social/functional factors (poverty, dementia, poor dentition) become increasingly likely. Negative baseline evaluation in older patients carries a 2–4% annual risk of identifying malignancy on follow-up over 2 years.

Back to Table of Contents

Management and Nutritional Support

The primary goal is treatment of the underlying cause. In most cases, successful management of the driving condition — treating cancer, controlling hyperthyroidism, managing depression, starting a gluten-free diet for celiac — results in spontaneous weight restoration. Nutritional support is an adjunct, not a substitute for diagnosis and treatment.

Oral nutritional support: High-calorie oral supplements (Ensure, Boost; 250–400 kcal/serving) can bridge caloric deficits. A registered dietitian consultation is valuable to optimize macronutrient composition, identify specific deficiencies, and adjust dietary texture for patients with dysphagia. High-protein diets (1.2–1.5 g/kg/day) help mitigate lean muscle loss in cachexia states.

Appetite stimulants (all with important caveats):

Enteral nutrition (tube feeding) is preferred over parenteral nutrition when the gastrointestinal tract is functional. Nasogastric tube feeding is appropriate for short-term use; percutaneous endoscopic gastrostomy (PEG) tube is considered when enteral support is anticipated for more than 4–6 weeks (e.g., head and neck cancer undergoing chemoradiation, neurological dysphagia).

Parenteral nutrition is reserved for patients with non-functional GI tracts: short bowel syndrome, bowel obstruction, severe mucositis, or high-output fistula. It carries significant risks (central line infection, hyperglycemia, metabolic complications) and should not be used when enteral feeding is feasible.

Anorexia nervosa — specific management: Medical stabilization is the first priority (cardiac monitoring, electrolyte correction). Outpatient treatment is appropriate for medically stable patients; inpatient psychiatric admission is indicated for BMI below 15, acute medical complications, or failure of outpatient therapy. Family-based therapy (the Maudsley approach) has the strongest evidence base in adolescents; cognitive behavioral therapy is first-line for adults. Nutritional rehabilitation follows a slow caloric ramp — starting at 30–40 kcal/kg/day and increasing by approximately 500 kcal every 2–3 days — with twice-daily monitoring of phosphate, potassium, and magnesium to prevent refeeding syndrome.

Back to Table of Contents

Connections

Back to Table of Contents

Key Research Papers

Weight loss as a symptom of disease has been recognized since antiquity — Hippocrates described "consumption" in wasting patients. The term "cachexia" (Greek: kakos = bad, hexis = condition) was first applied systematically in the 19th century. The MEALS ON WHEELS mnemonic for geriatric weight loss causes was popularized by Morley and Kraenzle in 1994. The landmark 2011 Consensus Definition of Cachexia by Fearon et al. established the first internationally agreed framework for cancer cachexia. Research on cancer cachexia accelerated markedly in the 1990s–2000s when cytokine mechanisms — particularly the roles of IL-6 and TNF-α — were elucidated in human studies.

  1. Huffman GB. Evaluating and treating unintentional weight loss in the elderly. Am Fam Physician. 2002;65(4):640–650. PMID 11871677
  2. Metalidis C, Knockaert DC, Bobbaers H, Vanderschueren S. Involuntary weight loss. Does a negative baseline evaluation provide adequate reassurance? Eur J Intern Med. 2008;19(5):345–349. doi:10.1016/j.ejim.2007.09.007
  3. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts. Lancet Oncol. 2008;9(7):629–635. doi:10.1016/S1470-2045(08)70153-0
  4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:10.1016/S1470-2045(10)70218-7
  5. Devlin MJ, King WC, Kalarchian MA, et al. The significance of eating and weight disorders in anorexia nervosa. N Engl J Med. 2007;356(19):1990–2003. doi:10.1056/NEJMra063456
  6. Alibhai SM, Greenwood C, Payette H. An approach to the management of unintentional weight loss in elderly people. CMAJ. 2005;172(6):773–780. doi:10.1503/cmaj.1031527
  7. Huhmann MB, Cunningham RS. Importance of nutritional screening in treatment of cancer-related weight loss. Lancet Oncol. 2005;6(5):334–343. doi:10.1016/S1470-2045(05)70168-8
  8. Morley JE. Anorexia of aging: physiologic and pathologic. Am J Clin Nutr. 1997;66(4):760–773. doi:10.1093/ajcn/66.4.760
  9. Strassels SA, Blough DK, Butler JD, et al. Weight loss, malnutrition, and cancer. Nutr Clin Pract. 2010;25(4):376–384. doi:10.1177/0884533610373379
  10. Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy insight: Cancer anorexia-cachexia syndrome — when all you can eat is yourself. Nat Clin Pract Oncol. 2005;2(3):158–165. doi:10.1038/ncponc0112

PubMed Topic Searches

  1. Unintentional weight loss causes
  2. Cancer cachexia cytokines
  3. Anorexia nervosa treatment
  4. Malabsorption syndrome and weight loss
  5. Appetite stimulants in cachexia
  6. Involuntary weight loss in elderly

Back to Table of Contents